Press releases

10 Jun, 2021

Q-linea has carried out a directed issue of 2.2 million shares, raising gross proceeds of SEK 301 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

10 Jun, 2021

Q-linea announces intention to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

7 Jun, 2021

Q-linea initiates US 510(k) clinical study for ASTar

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focused on developing and delivering solutions to diagnose infectious diseases accurately and rapidly, today announced that the company has started...

4 Jun, 2021

Commercial evaluation of the ASTar system in Europe started

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focused on developing and delivering solutions to diagnose infectious diseases accurately and rapidly, today announces the start of commercial evaluation...

25 May, 2021

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Today on 25 May 2021, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2020 in Uppsala, whereby the resolutions below were adopted.

6 May, 2021

Interim report 1 January – 31 March 2021

An intensive start to 2021 First quarter: 1 January – 31 March 2021 Net sales amounted to SEK 0.0 million (0.2). The operating result totalled SEK -63.8 million...

4 May, 2021

Q-linea achieves CE-IVD approval for ASTar

Q-linea AB (publ) (OMX: QLINEA) today announces that the company through very good study results has received a CE-IVD mark for the antibiotic susceptibility system ASTar®. Essential Agreement...

29 Apr, 2021

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL) – CORRECTION

Correction - addition of a new item, number 14, on the agenda and addition of the auditor's statement as to whether the annual general meeting’s guidelines for remuneration...

29 Apr, 2021

Invitation to presentation of Q-linea’s Interim report Q1, 2021 on May 6, 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim report for the period January – March 2021 on Thursday, May 6, 2021 at 07:30 (CEST). Q-linea...

26 Apr, 2021

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ) reg. no. 556729–0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 25 May 2021. In light of the...

26 Apr, 2021

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 25 May 2021,...

15 Apr, 2021

Q-linea publish the Annual report for 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2020 fiscal year has been published. The Annual Report is attached and can also...

31 Mar, 2021

Q-linea presents positive interim data from European trial

Q-linea AB (publ) (OMX: QLINEA) today announced very good interim results from the pivotal European trial for the antibiotic susceptibility system ASTar®. EA was over 94 percent, CA...

16 Mar, 2021

Q-linea signs first site for US study

Q-linea AB (publ) (OMX: QLINEA) today announced that the company has contracted Thermo Fisher Scientific as the first site to participate in the company's US clinical study for...

10 Mar, 2021

Q-linea has received first order on ASTar

Q-linea AB (publ) (OMX:QLINEA), today announced that the company’s global sales partner Thermo Fisher Scientific has placed their first order on ASTar® instruments and consumables. The value of...

18 Feb, 2021

Year-end report 1 January – 31 December 2020

Well prepared ahead of commercialisation Fourth quarter: 1 October - 31 December 2020 Net sales amounted to SEK 0.0 million (0.0). The operating result totalled SEK -57.1 million...

15 Feb, 2021

Invitation to presentation of Q-linea’s Year-end report 2020 on February 18, 2021

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year-end report for the period January – December 2020 on Thursday, February 18, 2021 at 07:30 a.m. CET.

10 Dec, 2020

Q-linea initiates pivotal clinical study for ASTar

Q-linea AB (publ) (OMX:QLINEA), today announced that the company has started the pivotal clinical study for ASTar in Europe. “It feels fantastic to have started the clinical study...

20 Nov, 2020

Jonas Jarvius, CEO of Q-linea presents at Life Science Day

On November 26 at 9.30 (CET) Jonas Jarvius, CEO at Q-linea AB presents the latest developments in the company at Redeye. The presentation is broadcast live and can...

10 Nov, 2020

Q-linea develops portable blood culture technology

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has started the development of a portable blood culture technology with the goal of shortening the time from...

5 Nov, 2020

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2020

ASTar has been tested at the Uppsala University Hospital before the start of studies Third quarter, 1 July – 30 September 2020 Net sales amounted to SEK 0.0 million...

29 Oct, 2020

Invitation to presentation of Q-linea’s Interim report Q3-2020 on November 5, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – September 2020 on Thursday, November 5, 2020 at 07:30 a.m. CET. Q-linea...

28 Oct, 2020

Webinar Tuesday November 10th: Equal and better care for everyone

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar with presentations followed by a Q&A session by CEO Jonas Jarvius, Research Director Mats Gullberg and Marketing &...

11 Sep, 2020

Q-linea enters into an agreement with Hvidovre Hospital as a participant in the clinical study

Q-linea AB (publ) (OMX:QLINEA), today announced that Hvidovre Hospital in Denmark will participate in the company's European pivotal clinical study, which will start in the autumn of 2020. Through...

4 Sep, 2020

Q-linea installs the first ASTar system at Uppsala University Hospital

Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate...

16 Jul, 2020

INTERIM REPORT 1 JANUARY – 30 JUNE 2020

Strong study results and virtual presentation of ASTar Second quarter, 1 April –30 June 2020 Net sales amounted to SEK 0.1 million (0.5). The operating result totalled SEK...

9 Jul, 2020

Invitation to presentation of Q-linea’s Interim report Q2-2020 on July 16, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – June 2020 on Thursday, July 16, 2020 at 07:30 a.m. CET. Q-linea...

30 Jun, 2020

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of June due to the...

2 Jun, 2020

Q-linea has carried out a directed issue of 4 million shares, raising proceeds of SEK 270 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

2 Jun, 2020

Q-linea announces intention to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OF AMERICA...

26 May, 2020

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-linea AB (publ) (OMX:QLINEA), Today on 26 May 2020, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2019 in Uppsala, whereby the...

25 May, 2020

Webinar Friday June 5th: How can we improve infection diagnostics with ASTar

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar on June 5at 2pm and 7pm CEST with presentations by CEO Jonas Jarvius, Research Director Mats Gullberg...

12 May, 2020

Q-linea announces positive results from prospective study with ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced positive results from a prospective patient study conducted together with Uppsala University Hospital. In the study, the ASTar system analyzed samples...

7 May, 2020

INTERIM REPORT 1 JANUARY – 31 MARCH 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar First quarter, 1 January –31 March 2020 Net sales amounted to SEK 0.2 million (0.4). The operating...

29 Apr, 2020

Invitation to presentation of Q-linea’s Interim report Q1-2020 on May 7, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – March 2020 on Thursday, May 7, 2020 at 07:30 a.m. CET. Q-linea...

27 Apr, 2020

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 26 May 2020, at 4 pm in...

24 Apr, 2020

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 26 May 2020,...

17 Apr, 2020

Q-linea publish the Annual report for 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2019 fiscal year has been published. The Annual Report is attached and can also...

26 Mar, 2020

Q-linea has solved the component problem

Q-linea AB (publ) (OMX: QLINEA), today announced that the problem discovered in October last year has now been solved. With respect to the component that previously caused a...

13 Feb, 2020

YEAR-END REPORT 1 JANUARY – 31 DECEMBER 2019

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar intensifies ahead of ASTar launch Fourth quarter, 1 October–31 December 2019 Net sales amounted to SEK 0.0...

12 Feb, 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has entered into a worldwide exclusive partnership with Thermo Fisher Scientific for the commercialization of ASTar. “We are very...

6 Feb, 2020

Invitation to presentation of Q-linea’s Year End Report Q4-2019 on February 13, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year End Report for the period January – December 2019 on Thursday, February 13, 2020 at 07:30 a.m....

31 Jan, 2020

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of January due to subscription...

7 Nov, 2019

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2019

A quarter of intense preparation Third quarter, 1 July - 30 September 2019 Net sales amounted to SEK 0.0 million (0.3). The operating result totalled SEK -35.8 million (-28.8). ...

31 Oct, 2019

Invitation to presentation of Q-linea’s Interim Report Q3-2019 on November 7, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – September 2019 on Thursday, November 7, 2019 at 07:30 a.m. CET. Q-linea...

30 Oct, 2019

Q-linea receives positive response from the FDA for the design of the company’s planned clinical study in the USA

Q-linea AB (publ) (OMX: QLINEA, announced today that the company has received the official response including a number of clarifications and very positive feedback from the US Food...

22 Oct, 2019

Q-linea postpones start of the clinical trials

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), today announced that the clinical trials, in the United States and Europe, for the company's first product ASTar® are expected to begin in the second...

3 Sep, 2019

Q-linea strengthens management team

UPPSALA, Sweden, 3 September, 2019 - Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced Thomas Fritz has been appointed...

31 Jul, 2019

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of July due to the...

18 Jul, 2019

INTERIM REPORT 1 JANUARY – 30 JUNE 2019

Launch preparations continue Second Quarter: 1 April–30 June 2019 Net sales amounted to SEK 0.5 million (0.3). The operating result totalled SEK -44.5 million (-35.7). The company reported a...

12 Jul, 2019

Q-linea strengthens management team

UPPSALA, Sweden, 12 July, 2019 - Q-linea AB (publ) (Nasdaq Stockholm:QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today...

11 Jul, 2019

Invitation to presentation of Q-linea’s Interim Report Q2-2019 on July 18, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 18, 2019 at 07:30 a.m. CET. Q-linea...

1 Jul, 2019

Issue and repurchase of class C shares for incentive program

By virtue of authorization from the annual general meeting held on 22 May 2019, the board of directors of Q-linea AB (publ) (“Q-linea”) has resolved to issue 117,424...

22 May, 2019

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Today on 22 May 2019, Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) held its annual general meeting for the financial year 2018 in Uppsala, whereby the following resolutions were...

3 May, 2019

INTERIM REPORT 1 JANUARY – 31 MARCH 2019

Final version of ASTar shows favourable results and garners positive reception Quarter: January–March 2019 Net sales amounted to SEK 0.4 million (0.3). The operating result totalled SEK -36.7 million...

26 Apr, 2019

Invitation to presentation of Q-linea’s Interim Report Q1-2019 on May 3, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – March 2019 on Friday, May 3, 2019 at 07:30 a.m. CET. Q-linea...

18 Apr, 2019

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Wednesday 22 May 2019, at 4 pm in...

17 Apr, 2019

Q-linea publish the Annual report for 2018

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2018 fiscal year has been published. The Annual Report is attached and can also...

15 Apr, 2019

Q-linea’s ASTar – a success on ECCMID

Q-linea AB (publ) (OMX: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, now presents the final design of ASTar...

12 Apr, 2019

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today the proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors. The nomination...

29 Mar, 2019

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of March due to the...

14 Mar, 2019

Q-linea can reach its main market faster than planned

Q-linea AB (publ) (OMX: QLINEA), today announced that the company's first product ASTar™ is expected to launch on the company’s main market, the U.S., three to four months...

14 Feb, 2019

YEAR-END REPORT 1 JANUARY–31 DECEMBER 2018

Successful capital raise and IPO on Nasdaq Stockholm Quarter: October–December 2018 Net sales amounted to SEK 0.3 million (1.5). Operating result totalled SEK -39.0 million (-21.8). The company reported...

4 Jan, 2019

Stabilization notice and end of the stabilization period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION...

28 Dec, 2018

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of December due to the...

18 Dec, 2018

Stabilization notice

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION...

6 Dec, 2018

Trading in Q-linea’s share commences tomorrow on Nasdaq Stockholm

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE...

23 Nov, 2018

Q-linea publishes prospectus for Initial Public Offering on Nasdaq

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE...